Insight, China's Pharmaceutical Industry

Company Drug

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced...

Company Drug

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Fineline Cube Jun 4, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical...

Company

Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year...

Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

Fineline Cube Jun 4, 2026

The U.S. Food and Drug Administration (FDA) released draft guidance on June 2, 2026, designed...

Policy / Regulatory

China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030

Fineline Cube Jun 4, 2026

China’s National Health Commission (NHC) has released the “Notice on Further Improving the Urban Community...

Company Deals

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Fineline Cube Jun 4, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical...

Company Deals

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Fineline Cube Jun 3, 2026

Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic...

Company Drug

Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations

Fineline Cube Jun 3, 2026

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from...

Company Medical Device

Genesis MedTech Secures CE Mark for World’s First Integrated Scissor-Type Ultrasonic Scalpel, Following 2025 China Approval

Fineline Cube Jun 3, 2026

Genesis MedTech, a Singapore-based medical device innovator, announced it has received CE Mark certification for...

Company Deals

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Fineline Cube Jun 3, 2026

Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX),...

Company Drug

Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World’s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule

Fineline Cube Jun 3, 2026

Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has...

Company Drug

Legend Biotech’s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed/Refractory B-Cell Lymphoma with No Serious Safety Events

Fineline Cube Jun 3, 2026

Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19/CD20...

Company Drug

Kelun-Biotech’s Novel B7-H3 ADC SKB500 Shows 42.7% Response Rate Across Multiple Solid Tumors in First-in-Human ASCO 2026 Presentation

Fineline Cube Jun 3, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) unveiled first-in-human clinical data for its investigational B7-H3-targeting...

Others

AbbVie’s AQUIPTA (Atogepant) Receives European Commission Approval for Acute Migraine Treatment, Expanding Beyond Preventive Use

Fineline Cube Jun 3, 2026

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...

Others

Xtalpi’s AI Biology Spin-off INFevo Secures Tens of Millions in Angel Funding to Build Virtual Cell System for Drug Discovery

Fineline Cube Jun 3, 2026

Xtalpi Inc. (HKG: 2228) announced that its AI biology subsidiary INFevo has completed an angel...

Company Drug

Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment

Fineline Cube Jun 3, 2026

Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration...

Others

CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus

Fineline Cube Jun 3, 2026

CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China’s...

Company Drug

AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial

Fineline Cube Jun 3, 2026

AstraZeneca plc (NYSE: AZN) announced updated results from the Phase III SERENA-6 clinical trial, demonstrating...

Company Drug

SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials

Fineline Cube Jun 3, 2026

Izalontamabbrengitecan (iza-bren), an EGFR and HER3-targeted antibody-drug conjugate (ADC) jointly developed by SystImmune (a subsidiary...

Company Drug

CSPC Pharmaceutical’s B7-H3 ADC SYS 6043 Shows 41.8% Response Rate in Phase I Solid Tumor Study

Fineline Cube Jun 3, 2026

CSPC Pharmaceutical Group Ltd. (HKG: 1093) presented Phase I clinical data for SYS 6043, a...

Insight, China's Pharmaceutical Industry

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations

Genesis MedTech Secures CE Mark for World’s First Integrated Scissor-Type Ultrasonic Scalpel, Following 2025 China Approval

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World’s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule

Legend Biotech’s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed/Refractory B-Cell Lymphoma with No Serious Safety Events

Kelun-Biotech’s Novel B7-H3 ADC SKB500 Shows 42.7% Response Rate Across Multiple Solid Tumors in First-in-Human ASCO 2026 Presentation

AbbVie’s AQUIPTA (Atogepant) Receives European Commission Approval for Acute Migraine Treatment, Expanding Beyond Preventive Use

Xtalpi’s AI Biology Spin-off INFevo Secures Tens of Millions in Angel Funding to Build Virtual Cell System for Drug Discovery

Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment

CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus

AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial

SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials

CSPC Pharmaceutical’s B7-H3 ADC SYS 6043 Shows 41.8% Response Rate in Phase I Solid Tumor Study

You Missed

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added